Cushing syndome

Reading File

Finding Sources

Searching PubMed

"Cushing syndrome"[MeSH Terms] AND diagnosis

Reading File

Loading Image

Reading File

Loading Image

Reading File

I now have comprehensive data from multiple authoritative sources. Let me compile the full answer.

Cushing Syndrome

Definition

Cushing syndrome is the clinical state resulting from prolonged, excessive exposure to glucocorticoids (cortisol). The term "Cushing syndrome" is an umbrella term for all causes of hypercortisolism, whereas "Cushing disease" specifically refers to hypercortisolism caused by an ACTH-secreting pituitary adenoma. - Campbell Walsh Wein Urology, p. 3133; Henry's Clinical Diagnosis, p. 1804

Epidemiology

Endogenous Cushing syndrome is rare: incidence 0.7 to 2.4 per million per year
Most common cause overall is iatrogenic (exogenous glucocorticoid therapy)
Among endogenous causes, ACTH-dependent types account for >80% of cases
Cushing disease (pituitary adenoma) accounts for ~68% of endogenous cases; ectopic ACTH ~12%; adrenal tumors <20%

Pathophysiology and Classification

The HPA axis normally operates as a negative-feedback loop: CRH (hypothalamus) stimulates ACTH (anterior pituitary) which drives cortisol production in the adrenal zona fasciculata (up to 20 mg/day). Cortisol then feeds back to suppress both CRH and ACTH. Cushing syndrome arises when this loop is disrupted. - Campbell Walsh Wein Urology, p. 3133-3134

Mechanisms of Cushing syndrome - ACTH-dependent (pituitary tumor), ectopic ACTH tumor, and ACTH-independent (adrenal tumor) pathways

Causes of Cushing Syndrome

Category	Mechanism	Examples
Exogenous (iatrogenic)	Exogenous glucocorticoids suppress HPA axis	Long-term steroid therapy (most common overall)
ACTH-Dependent	Excess ACTH drives bilateral adrenal cortisol overproduction	Pituitary adenoma (Cushing disease), ectopic ACTH (small cell lung cancer, carcinoid), ectopic CRH-secreting tumor
ACTH-Independent	Adrenal autonomously produces cortisol; ACTH is suppressed	Adrenal adenoma (80% of unilateral), adrenocortical carcinoma (ACC), bilateral macronodular hyperplasia (AIMAH), PPNAD

Rare adrenal causes:

AIMAH (ACTH-independent bilateral macronodular adrenal hyperplasia): <1% of cases; massive bilateral glands (each >60 g, sometimes >200 g)
PPNAD (primary pigmented nodular adrenocortical disease): <1% of cases; normal-sized glands with black/brown nodules; half are associated with Carney complex (autosomal dominant)

Clinical Features

Systemic effects of hypercortisolism on organ systems

Cardinal Signs and Symptoms

Characteristic features (more specific for Cushing syndrome):

Central (truncal) obesity with relatively thin extremities
Moon facies (facial rounding/plethora)
Buffalo hump (dorsocervical fat pad)
Purple/violaceous abdominal striae (>1 cm wide)
Easy bruisability
Proximal muscle weakness/myopathy
Thin skin

Metabolic and systemic effects:

Hypertension (salt and water retention)
Hyperglycemia / type 2 diabetes (peripheral insulin resistance, gluconeogenesis)
Dyslipidemia
Hypokalemia (especially with ectopic ACTH - massive cortisol has mineralocorticoid effect)
Urolithiasis
Osteoporosis and pathological fractures
Increased susceptibility to infections (immunosuppression)

Neuropsychiatric:

Depression, anxiety, cognitive impairment, psychosis
Glaucoma

Reproductive:

Hypogonadism, menstrual irregularity, decreased libido
Hirsutism and acne (from androgen excess)

Note on ectopic ACTH syndrome: Typically presents with rapid onset, severe hypokalemia, hyperpigmentation (from high ACTH/MSH), and metabolic alkalosis, often without the classic Cushingoid body habitus (because the underlying malignancy causes weight loss).

Pseudo-Cushing Syndrome

Several physiological states mimic Cushing syndrome by activating the HPA axis without a neoplastic source. Important to distinguish clinically:

With some Cushingoid features	Without Cushingoid features
Pregnancy	Physical stress, surgery, pain
Depression	Malnutrition / anorexia nervosa
Alcohol dependence	Intense chronic exercise
Morbid obesity	Hypothalamic amenorrhea
Poorly controlled diabetes

Campbell Walsh Wein Urology, p. 3138; Tietz Textbook of Laboratory Medicine, p. 2242

Diagnosis

Diagnosis is a two-phase process: screening followed by confirmatory and localizing tests. - Henry's Clinical Diagnosis, p. 1808

Phase 1 - Screening Tests (any one of three)

Test	Principle	Notes
24-hour urinary free cortisol (UFC)	Measures unbound, biologically active cortisol; integrated over 24 hours	Normal upper limit: 110-138 nmol/24h (40-50 µg/24h) with HPLC/mass spec; values >4x ULN are diagnostic; measure creatinine to confirm adequacy; unreliable if GFR <30 mL/min
Overnight 1 mg dexamethasone suppression test (DST)	Give 1 mg dexamethasone at 11 PM; measure 8 AM serum cortisol - failure to suppress (<50 nmol/L) is abnormal	Preferred screening for mild/subclinical cases; can be affected by drugs altering CYP3A4 metabolism of dexamethasone
Late-night salivary cortisol (LNSC) or midnight plasma cortisol (MSC)	Exploits the key abnormality in ALL types of Cushing syndrome: loss of nocturnal cortisol nadir	Salivary cortisol is practical outpatient test; midnight plasma cortisol requires inpatient testing

Key diagnostic principle: Even in very mild Cushing syndrome, the hallmark abnormality is the inability to suppress cortisol at night - morning cortisols may still be within normal range. - Campbell Walsh Wein Urology, p. 3137

Laboratory findings in confirmed Cushing syndrome:

Elevated serum/urinary/salivary cortisol
Loss of circadian rhythm of ACTH and cortisol
Failure to suppress cortisol with dexamethasone

Henry's Clinical Diagnosis, p. 1802

Phase 2 - Confirmatory and Localizing Tests

Once hypercortisolism is confirmed:

Step 1: Measure plasma ACTH

ACTH suppressed (<10 pg/mL) → ACTH-independent (adrenal source) → CT/MRI adrenal glands
ACTH elevated or normal → ACTH-dependent → proceed to differentiate pituitary vs. ectopic

Step 2: Differentiate pituitary vs. ectopic ACTH

High-dose DST (8 mg dexamethasone): Pituitary Cushing disease usually suppresses (>50%); ectopic ACTH typically does not suppress
CRH stimulation test: Pituitary source shows ACTH and cortisol rise; ectopic source shows no rise
Bilateral inferior petrosal sinus sampling (IPSS): Gold standard for distinguishing pituitary vs. ectopic; central:peripheral ACTH ratio >2 basal or >3 after CRH = pituitary source
MRI pituitary: Microadenomas (≤10 mm) may be too small to visualize; 40-50% of pituitary adenomas are radiographically occult

Imaging:

Pituitary MRI (gadolinium) for Cushing disease
CT chest/abdomen for ectopic source (small cell lung, bronchial carcinoid, thymic tumors, pancreatic NET, pheochromocytoma)
CT/MRI adrenal for adrenal causes; adrenal adenomas typically lipid-rich, homogeneous, <4 cm

Treatment

Treatment depends on the underlying etiology. Surgery is first-line for most endogenous causes.

Cushing Disease (Pituitary Adenoma)

Transsphenoidal pituitary surgery (TSS): First-line; remission rates 65-90% for microadenomas
Radiation therapy (stereotactic radiosurgery) if TSS fails or is not feasible
Bilateral adrenalectomy: Used when pituitary treatment fails; risk of Nelson syndrome (expansion of residual ACTH-secreting tumor due to loss of cortisol feedback)

Adrenal Cushing Syndrome

Unilateral adrenalectomy for adenoma or unilateral ACC (laparoscopic preferred)
Bilateral adrenalectomy for PPNAD or AIMAH
Post-adrenalectomy: glucocorticoid replacement is mandatory due to contralateral adrenal suppression (Cushingoid phenotype resolves in 7-9 months typically)
ACC: multimodal therapy with mitotane (adrenolytic agent)

Ectopic ACTH Syndrome

Surgical resection of the primary tumor when identified and resectable
If occult/unresectable: bilateral adrenalectomy to control hypercortisolism

Preoperative Medical Management

Adrenal steroidogenesis inhibitors are used preoperatively (especially in severe cases) or as bridging therapy:

Metyrapone - inhibits 11β-hydroxylase (most commonly used)
Ketoconazole - inhibits multiple steroidogenic enzymes (CYP11A1, CYP17A1, CYP11B1)
Osilodrostat - potent 11β-hydroxylase inhibitor (newer agent)
Mifepristone - glucocorticoid receptor antagonist (useful when cortisol cannot easily be lowered)
Pasireotide - somatostatin analog; targets pituitary in Cushing disease

Perioperative Care for Cushing Surgery

Issue	Management
Severe hypercortisolism	Preoperative metyrapone to reduce cortisol burden
Hyperglycemia	Tight glycemic control
Thromboembolism	High risk - prophylaxis required
Infection	Perioperative antibiotics; immunosuppression increases risk
Adrenal insufficiency post-op	Intraoperative and postoperative steroid replacement
Hypertension/hypokalemia	Correct before surgery

Campbell Walsh Wein Urology, p. 3191-3192

Complications of Untreated Cushing Syndrome

Cardiovascular disease (accelerated atherosclerosis, LVH)
Osteoporosis and fragility fractures
Type 2 diabetes and metabolic syndrome
Opportunistic infections and impaired wound healing
Thromboembolic events (DVT, PE) - cortisol is prothrombotic
Psychiatric illness (depression is present in ~50% of patients)
Increased mortality if untreated

Recent Evidence (2024-2026)

A 2024 systematic review and meta-analysis (Hinojosa-Amaya et al., Pituitary, PMID 38888685) examined the challenge of differentiating true Cushing syndrome from non-neoplastic hypercortisolism (pseudo-Cushing) - a clinically important diagnostic conundrum. A 2025 meta-analysis (Piasecka et al., Eur J Endocrinol, PMID 40455890) reported on survival outcomes specifically in ectopic Cushing syndrome. These papers confirm that diagnostic discrimination and prognosis in ectopic disease remain active areas of research.

Sources: Campbell Walsh Wein Urology (9780323546423); Henry's Clinical Diagnosis and Management by Laboratory Methods (9780323673204); Tietz Textbook of Laboratory Medicine, 7th ed. (9780323775724); Textbook of Family Medicine, 9e (9780323239905)

This is a shared conversation. Sign in to Orris to start your own chat.